Sequoia Financial Advisors LLC Cuts Stake in Eli Lilly and Company $LLY

Key Points

• Sequoia Financial Advisors trimmed its Eli Lilly stake by 3.0% in the first quarter, selling 4,385 shares and leaving it with 143,305 shares valued at about $131.8 million.
• Eli Lilly reported strong quarterly results, posting EPS of $8.55 and revenue of $19.8 billion, both well above analyst expectations, with revenue up 55.5% year over year.
• Analysts remain bullish on the stock, with multiple firms raising price targets and the consensus rating standing at Moderate Buy with an average target of $1,263.41.

Sequoia Financial Advisors LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 143,305 shares of the company's stock after selling 4,385 shares during the period. Sequoia Financial Advisors LLC's holdings in Eli Lilly and Company were worth $131,808,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in LLY. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock valued at $88,087,193,000 after buying an additional 1,006,885 shares during the last quarter. State Street Corp raised its position in Eli Lilly and Company by 1.8% in the 4th quarter. State Street Corp now owns 35,361,916 shares of the company's stock worth $38,002,744,000 after buying an additional 635,358 shares during the last quarter. Morgan Stanley lifted its stake in Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock valued at $16,757,510,000 after acquiring an additional 407,166 shares during the period. Capital World Investors lifted its stake in Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock valued at $16,154,619,000 after acquiring an additional 61,851 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Eli Lilly and Company by 10.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock valued at $16,024,022,000 after acquiring an additional 1,432,069 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY traded down $27.89 during trading on Friday, hitting $1,189.06. The company's stock had a trading volume of 2,008,208 shares, compared to its average volume of 2,892,553. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The firm has a market cap of $1.12 trillion, a PE ratio of 42.24, a P/E/G ratio of 1.51 and a beta of 0.51. The business's 50 day simple moving average is $1,098.66 and its 200-day simple moving average is $1,033.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.81 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's payout ratio is currently 24.58%.

Analyst Ratings Changes

LLY has been the subject of several research reports. Leerink Partners boosted their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a report on Thursday, June 25th. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an "overweight" rating in a research report on Monday. BMO Capital Markets reiterated an "outperform" rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Weiss Ratings raised Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a report on Wednesday, July 1st. Finally, Truist Financial upped their price objective on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a "buy" rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $1,263.41.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and kept a buy rating, signaling confidence that the company still has meaningful upside after its recent run. Benzinga article
• Positive Sentiment: Lilly announced that its Phase 2 neuropathic pain trial reached completion, adding another potentially valuable pipeline asset beyond its blockbuster GLP-1 franchise. TipRanks article
• Positive Sentiment: News flow highlighting record GLP-1 adoption and accelerating sales remains supportive, since Lilly’s obesity and diabetes drugs continue to be the main driver of earnings momentum. Motley Fool article
• Positive Sentiment: Additional analyst commentary has been upbeat, with other firms also lifting targets and framing Lilly as one of the strongest growth names in healthcare. TheStreet article
• Neutral Sentiment: Institutional buying and “best mutual funds” lists suggest Lilly remains a favored large-cap healthcare holding, but this is more a sentiment indicator than a direct catalyst. Yahoo Finance article
• Negative Sentiment: Tampa General’s lawsuit over allegedly pulled 340B discounts adds legal and reimbursement risk, which could create some investor caution around Lilly’s pricing and hospital-channel relationships. Healthcare Finance News article

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.